Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Wuhan's XW Labs Gains US Orphan Drug Status for Narcolepsy Drug

publication date: Jun 24, 2019

XW Labs of Wuhan received US Orphan Drug Designation status for its lead molecule, a clinical-stage treatment for narcolepsy. XW develops novel small molecule therapeutics for CNS disorders. Narcolepsy, an orphan disease that affects 1 in 2,000 people, is caused by a loss of hypocretin neuronal cells, leading to abnormal regulation of the sleep-wake cycle. XWL-008 is aimed at treating the two major symptoms of narcolepsy, excessive daytime sleepiness and cataplexy, with fewer side effects than current medications. XW is planning to start a Phase III trial of XWL-008. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital